VX-264

Cell therapy

Discontinuedsponsor decision

Evidence outlook · program status

Discontinued (2025-03-28), after a negative readout

On 28 March 2025 Vertex announced results from the Phase 1/2 study of VX-264 (NCT05791201) and said the programme will not advance further in clinical development. Vertex later stated that the study did not meet its efficacy endpoint and took a $379.0 million impairment charge for VX-264. The registry record stays open for long-term follow-up only. The trials below are preserved as the program's evidence history; no evidence signal is assigned to a program the sponsor has stopped.

Source for the program status

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 1/2 (1)
Other / comorbidity
NCT05791201 · Vertex Pharmaceuticals Incorporated
2023-05-16 – 2027-03-12 · Type 1 Diabetes
What this study did

Competitive landscape

Other Pancreatic islet cell replacement drugs

Zimislecel. Compare all 2 Pancreatic islet cell replacement drugs

1 other tracked programme targets this mechanism, 1 of them ahead of this one.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
VX-264: this drugDiscontinuedCell therapyPancreatic islet cell replacementnot yet gradedNo reviewed efficacy summary
Zimislecel
Phase 3(overall)
Cell therapyPancreatic islet cells (VX-880 is a stem cell-derived therapy, not a small molecule drug), Pancreatic islet cell replacementnot yet gradedNo reviewed efficacy summary

Upcoming events

(1 total)

Development was discontinued on 2025-03-28 (source ↗). ClinicalTrials.gov still lists the estimated primary-completion dates below; they are not pending readouts.

2027 (1)
March 2027 (1)
Phase 1/2Type 1 DiabetesActive not recruitingProgramme discontinued
Est. primary completion 2027-03-12 · NCT05791201 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

28 March 2025Topline resultPhase 1/2 study of VX-264 (NCT05791201) did not meet its efficacy endpoint; programme discontinued
Vertex Pharmaceuticals · Source ↗